BioMarin Pharmaceutical Inc. (BMRN)
Nasdaq: BMRN · Pharmaceutical Preparations · Novato, CA · filing with the SEC since 1999
Grade6.5
◀ Past 7.2● Present 6.6▶ Future 5.7
Who owns BioMarin Pharmaceutical Inc.
As filed with the SECHolders of 5% or more
3
Blackrock, Inc. holds 9.1% of Common Stock, as its SCHEDULE 13G/A filed Jan 21, 2026 says.
Directors and officers
18
report now, of 33 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
Blackrock, Inc.
SCHEDULE 13G/A · filed Jan 21, 2026 · Common Stock · 10.8% in Apr 29, 2025
Primecap Management Co/ca/
Vanguard Capital Management
SCHEDULE 13G · filed Apr 29, 2026 · Common Stock
Capital Research Global Investors
SCHEDULE 13G/A · filed May 13, 2025 · Common Stock · reported falling below 5%, from 6.8% in Feb 13, 2025
Viking Global Investors LP
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, par value $0.001 per share · reported falling below 5%, from 6.4% in Aug 14, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%
What BMRN reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Inozyme Pharma, Inc
A company bought · asset acquisition · owns, named in the 10-K filed Feb 26, 2026
2 subsidiaries in 1 country, from the list filed with the 10-K filed Feb 26, 2026.
Insider tradesForm 4
5sales
0purchases
0sales on a scheduled plan
3people selling
$4.3Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 1, 2025 to Oct 1, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 1, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window3 of 33 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Davis George Eric | EVP, Chief Legal Officer | 2 | $2.8M | 0 | 0 | $0 |
| Guyer Charles Greg | EVP, Chief Technical Officer | 1 | $1.0M | 0 | 0 | $0 |
| Friberg Gregory R | EVP, Chief R&D Officer | 2 | $600,000 | 0 | 0 | $0 |